Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies SureSelect Human All Exon V8

Agilent Technologies has launched its SureSelect Human All Exon V8 tool. The firm said the product is a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GenCode. The tool also covers the TERT promoter and hard-to-capture exons. The firm said the new design spans a 35.1 Mb target region of the human genome and delivers excellent enrichment performance for more uniform coverage, as well as efficient and cost-effective exome sequencing. 

Agilent offers the new design in three versions: routine exome sequencing (Exome v8); clinical research sequencing (v8 Clinical Plus); and translational research (v8 UTR Plus). 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.